None listed
Conditions
Interventions
Intervention1: IRL-1620 For Injection (PMZ-1620): Cohort 1: Total three (3) doses of 0.3 µg/kg each, to be administered at an interval of four hours (total dose/day: 0.9 µg/kg body weight).
Cohort
Sponsors
Pharmazz India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: •Sex: Male •Age: 18-60 yr old, both inclusive •Having a Body Mass Index (BMI) between 18.5-28 kg/m2 (both inclusive) and body weight not less than 45 kg •Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; and to comply with the requirements of the entire study •Voluntarily given written informed consent to participate in this study •Be of normal health as determined by the principal investigator from medical history, physical examination and laboratory investigations, 12-lead ECG and chest X-ray of the subjects performed within 10 days prior to the admission of the study •Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, power drinks) and grapefruit (juice) from 48 h prior to each admission until study completion.
Exclusion criteria
Exclusion criteria: •Employees of Clinical site or Pharmazz India Private Limited •Not willing to use contraceptives (preferably condoms) during sexual activity for the period of 3 months from the date of check-in •History of hypersensitivity and/or intolerance to PMZ-1620 or any other related compounds. •History of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study. •Clinically abnormal ECG and Chest X-ray. •Physical findings: clinically relevant abnormal physical findings (including body temperature) suggesting underlying pathologies or those which could interfere with the objectives of the study. •Subjects with impaired renal function as measured by glomerular filtration rate •Laboratory values that are significantly different than the normal reference range and/or are deemed to be of clinical significance by the investigator •Presence of reactive disease markers of HIV 1 and II, HBsAg, HCV or VDRL. •Positive for alcohol breath test and/or urine drug screen (barbiturates, benzodiazepines, amphetamine, cocaine, opiates, tetra-hydro cannabinol). •Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations. •Diseases: relevant history of renal, hepatic, cardiovascular, respiratory, skin, haematological, endocrine, neurological or gastrointestinal diseases. History of depression, psychosis, schizophrenia or any other severe psychiatric diseases, or epilepsy, or any other illness that may interfere with the aim of the study. History of any significant illness in the 4 weeks preceding the screening •Medications: history of intake of any medications including over the counter medications (OTC) and any herbal agents at least 4 weeks period prior to IP administration. •Investigational drug trials: participation in the evaluation of any drug in the 3 months prior to the start of the study (dosing with IMP). •Blood donation: Subjects who, through completion of this study, would have donated and/or lost more than 300 mL of blood in the past 12 weeks Note: In case the blood loss is •Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period. •History of drug dependence or alcoholics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine safety and tolerability of PMZ-1620 after Multiple Ascending Doses (MAD).Timepoint: Vitals: At screening, admission, Pre-dose and 0.17, 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 18.0, 24.0, 36.0 and 48.0 hrs post-dose and at follow-up visit on Day 5-7. | — |
Secondary
| Measure | Time frame |
|---|---|
| Description of pharmacodynamics of PMZ-1620 in terms of systolic and diastolic blood pressure, pulse rate, respiratory rate, heart rate, QTcF (QTcF defined as QT interval corrected for heart rate using Fridericiaâ??s formula) after MAD.Timepoint: ECG: At screening, admission, pre-dose and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 18.0, 24.0, 36.0 and 48.0 hours post-dose and at follow-up visit on Day 5-7. | — |
Countries
India
Contacts
Public ContactDr Manish S Lavhale
Pharmazz India Private Limited
Outcome results
None listed